These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27141991)

  • 1. Discrimination of Active and Weakly Active Human BACE1 Inhibitors Using Self-Organizing Map and Support Vector Machine.
    Li H; Wang M; Gong YN; Yan A
    Comb Chem High Throughput Screen; 2016; 19(6):470-80. PubMed ID: 27141991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification of Aurora-A Kinase Inhibitors Using Self-Organizing Map (SOM) and Support Vector Machine (SVM).
    Wang L; Wang Z; Yan A; Yuan Q
    Mol Inform; 2011 Jan; 30(1):35-44. PubMed ID: 27467876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification models of HCV NS3 protease inhibitors based on support vector machine (SVM).
    Wang M; Xuan S; Yan A; Yu C
    Comb Chem High Throughput Screen; 2015; 18(1):24-32. PubMed ID: 25410306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-Organizing Map (SOM) and Support Vector Machine (SVM) Models for the Prediction of Human Epidermal Growth Factor Receptor (EGFR/ ErbB-1) Inhibitors.
    Kong Y; Qu D; Chen X; Gong YN; Yan A
    Comb Chem High Throughput Screen; 2016; 19(5):400-11. PubMed ID: 27074760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).
    Qin Z; Wang M; Yan A
    Bioorg Med Chem Lett; 2017 Jul; 27(13):2931-2938. PubMed ID: 28501513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors.
    Qu D; Yan A; Zhang JS
    SAR QSAR Environ Res; 2017 Feb; 28(2):111-132. PubMed ID: 28235391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classification of beta-site amyloid precursor protein cleaving enzyme 1 inhibitors by using machine learning methods.
    Singh R; Ganeshpurkar A; Ghosh P; Pokle AV; Kumar D; Singh RB; Singh SK; Kumar A
    Chem Biol Drug Des; 2021 Dec; 98(6):1079-1097. PubMed ID: 34592057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Support Vector Machine (SVM) for Classification of Selectivity of H1N1 Neuraminidase Inhibitors.
    Li Y; Kong Y; Zhang M; Yan A; Liu Z
    Mol Inform; 2016 Apr; 35(3-4):116-24. PubMed ID: 27491921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SAR and QSAR models of cyclooxygenase-1 (COX-1) inhibitors.
    Xi Y; Qin Z; Yan A
    SAR QSAR Environ Res; 2018 Oct; 29(10):755-784. PubMed ID: 30274533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computer modeling in predicting the bioactivity of human 5-lipoxygenase inhibitors.
    Zhang M; Xia Z; Yan A
    Mol Divers; 2017 Feb; 21(1):235-246. PubMed ID: 27904990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discriminating of ATP competitive Src kinase inhibitors and decoys using self-organizing map and support vector machine.
    Yan A; Hu X; Wang K; Sun J
    Mol Divers; 2013 Feb; 17(1):75-83. PubMed ID: 23117252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Silico Models to Discriminate Compounds Inducing and Noninducing Toxic Myopathy.
    Hu X; Yan A
    Mol Inform; 2012 Jan; 31(1):27-39. PubMed ID: 27478175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classification of Aurora B kinase inhibitors using computational models.
    Liu R; Nie X; Zhong M; Hou X; Xuan S; Yan A
    Comb Chem High Throughput Screen; 2014 Feb; 17(2):114-23. PubMed ID: 24152178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using self-organizing map (SOM) and support vector machine (SVM) for classification of selectivity of ACAT inhibitors.
    Wang L; Wang M; Yan A; Dai B
    Mol Divers; 2013 Feb; 17(1):85-96. PubMed ID: 23124952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Moussa CE
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAR study on inhibitors of GIIA secreted phospholipase A
    Zhang S; Li Y; Qin Z; Tu G; Chen G; Yan A
    Chem Biol Drug Des; 2019 May; 93(5):666-684. PubMed ID: 30582300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
    Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
    Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of new BACE1 inhibitors using Pharmacophore and Molecular dynamics simulations approach.
    Dhanabalan AK; Kesherwani M; Velmurugan D; Gunasekaran K
    J Mol Graph Model; 2017 Sep; 76():56-69. PubMed ID: 28710924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [BACE1 inhibitors for the treatment of Alzheimer disease].
    Tomita T
    Nihon Rinsho; 2016 Mar; 74(3):427-31. PubMed ID: 27025081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors.
    Mancini F; De Simone A; Andrisano V
    Anal Bioanal Chem; 2011 Jun; 400(7):1979-96. PubMed ID: 21503735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.